Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Credit: Shutterstock / LightField Studios. AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

AstraZeneca expects a regulatory decision ... At the same meeting late last week the CHMP said that diabetes drug Forxiga (dapagliflozin) could have its label changed to include new cardiovascular ...

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduction, better weight ...

A NEW SET OF TARIFFS BY THE TRUMP ADMINISTRATION WILL TAKE EFFECT, AND THEY COULD DRAMATICALLY CHANGE THE WAY YOU GET ...

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Major pharmaceutical companies like Pfizer and AstraZeneca operate in Mexico ... that come from Canada include HIV and AIDS medications, and diabetes medications. Several U.S. states, including ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...